As per the clinical trial protocol approved, 150 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care. Treatment duration is a maximum of 14 days and the total study duration will be a maximum for 28 days from randomisation.
Pharmaceutical and biotechnology major Wockhardt on Monday said it would invest Rs 50 crore (Rs 500 million) for setting up a research and development centre in Aurangabad.
The Oxford/AstraZeneca vaccine is also being produced as part of a tie-up by the Serum Institute of India.
'The focus for value creation will be on all business segments.'
'I cannot cope with the demand. It will take us a couple of months to ramp up production.'
In the midst of third wave of COVID-19, Finance Minister Nirmala Sitharaman has come up with an impactful Budget which is balanced, fiscally prudent and growth-oriented, the USA India Chamber of Commerce has said. President of the Boston-based USA India Chamber of Commerce (USAIC) Karun Rishi, however, said it is a matter of concern that the budget lacks tangible measures to increase revenue generation. "Opting to keep the fiscal deficit at 6.9 per cent and increase capital expenditure by 35 per cent is a masterstroke. "The annual budget estimates the effective capital expenditure of Rs 10.68 lakh crore in 2022-23, making up about 4.1 per cent of the GDP," he said. "A phenomenal increase in the government's capital expenditure is likely to facilitate the expenditures on infrastructure and create jobs.
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
The average expenditure of pharmaceutical companies on research and development has increased four times in the last five years.
Companies that are developing biosimilars (for regulated markets) or have portfolio of new chemical entities (NCEs) under development.
It is a Budget with a strong emphasis on agriculture, education, healthcare and infrastructure.
The PhRMA's observation is significant against the backdrop of Swiss pharma major Novartis AG's decision to relocate its R&D investments from India.
'However, we have seen weakness in our active pharmaceutical ingredients business.'
Trade generic drugs (medicines that are sold directly through distributors) are fast becoming a key segment for domestic pharma firms as volume growth slows in the overall market. Big companies like Cipla and Alkem have a significant presence in the segment but recently, players like Torrent Pharmaceuticals and Dr Reddy's Laboratories (DRL) have also entered this market. What is driving big pharma's focus on trade generics? The volume growth in the Indian Pharma Market (IPM) has come down from 5.6 per cent in FY16 to 0.1 per cent in FY23.
The government on Tuesday said it is considering forming a venture capital fund of Rs 2,000 crore (Rs 20 billion) to promote research and development (R&D) in the pharmaceutical sector.
Health sector in India has seen some of the most dramatic growth stories in past decade. Ranging from improved health care facilities to low cost treatment, the success of the health sector has been primarily driven by private enterprise.
The Indian pharma industry is estimated to grow at 9-11 per cent in 2021-22 and in the next few quarters, it will be driven by domestic and emerging markets, according to ratings agency ICRA. In a sample of 21 Indian pharmaceutical companies, ICRA said revenue growth was moderate at 6.4 per cent in the second quarter of FY22, down from 16 per cent in the first quarter of 2021-22. The normalisation of the base and pricing pressures in the US market were the major reasons for slowing growth momentum in Q2 FY22, even as growth under domestic and emerging markets remained healthy, ICRA said in a statement.
.jpg)
To focus on molecules at advanced stage of development; move to impact 200 scientists.
Sohini Das chats with MD of Zydus Cadila Healthcare Pankaj R Patel & his son Sharvil Patel.
Currently, FDI up to 100 per cent is allowed in the drugs and pharmaceuticals on the automatic route.
There is no doubt that patients are the ultimate beneficiaries of pharmaceutical research and development. Thousands of public health needs go unmet each day simply because there is still a cure out there waiting to be found. Product patents serve as encouragement to innovation, providing impetus to both investors and innovators. It has been argued that by denying product patents, India will encourage domestic generic production and, therefore, access to medicines.
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
The Department of Industrial Policy and Promotion in its draft Cabinet has proposed to further tighten the rules for foreign direct investment in brownfield pharmaceutical sector.
The NPPA letter was issued to GSK on Wednesday.
Washington-based Carlyle Group has invested $20 million in Ahmedabad-based pharmaceutical company Claris Lifesciences Limited to fund its Rs 190 crore (Rs 1.9 billion) expansion plans.
This is a one-year distance learning course.
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
The Tata group has earmarked about Rs 1,000 crore (Rs 10 billion) for investment over the next four years in Advinus Therapeutics, a joint venture floated by it and ex-Ranbaxy research head Rashmi Barbhaiya.
We believe that our R&D business has tremendous potential for growth and long-term profitability.
